Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The companyâs lead product candidate, AT-001, is a novel aldose reductase inhibitor (ARI) that is being developed for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart. Applied Therapeutics is also developing AT-007, a central nervous system penetrant ARI, for the treatment of Galactosemia, a rare pediatric metabolic disease. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of diabetic retinopathy. Source
No articles found.
Guardion Health Sciences is at the forefront of early detection, intervention and ...
Guardion Health Sciences is at the forefront of...
Intec Pharma is a clinical-stage biopharmaceutical company focused on developing d...
Intec Pharma is a clinical-stage biopharmaceuti...
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers...
At Biogen, our mission is clear: we are pioneer...
Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing a...
Supernus Pharmaceuticals, Inc. is a pharmaceuti...
Translate Bio is a leading mRNA therapeutics company developing a new class of pot...
Translate Bio is a leading mRNA therapeutics co...
Fennec Pharmaceuticals, Inc., (NASDAQ: FENC; TSX: FRX) is a specialty pharmaceutic...
Fennec Pharmaceuticals, Inc., (NASDAQ: FENC; TS...
Alexion (NASDAQ: ALXN) is a global biopharmaceutical company focused on serving pa...
Alexion (NASDAQ: ALXN) is a global biopharmaceu...
Join the National Investor Network and get the latest information with your interests in mind.